SCHEMBL29734522

SCHEMBL29734522

COc1ccc(C(=C2CCN(C(=O)OC(C)(C)C)CC2)c2ccccn2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTAFR P25105 1/20 0.51
▸ CFTR P13569 2/20 0.47
▸ RAB9A P51151 2/20 0.45
▸ PDE4B Q07343 3/20 0.45
▸ PDE4A P27815 2/20 0.45
▸ PDE4C Q08493 2/20 0.45
▸ PDE4D Q08499 2/20 0.45
▸ GPR119 Q8TDV5 1/20 0.44
▸ FNTA P49354 1/20 0.43
▸ FNTB P49356 1/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ GRM5 P41594 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ KDR P35968 1/20 0.42
▸ POLB P06746 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22491587 1.00 PTAFR (0.51) PTAFRCFTRRAB9APDE4BPDE4A
SCHEMBL21381712 0.87 PTAFR (0.55) PTAFRRAB9APDE4BFNTAFNTB
SCHEMBL22491440 0.84 LMNA (0.50) CFTRPDE4BPDE4APDE4CPDE4D
SCHEMBL29734416 0.84 LMNA (0.50) CFTRPDE4BPDE4APDE4CPDE4D
SCHEMBL23211806 0.82 POLB (0.46) CFTRPDE4BPDE4APDE4CPDE4D
SCHEMBL30567965 0.82 POLB (0.46) CFTRPDE4BPDE4APDE4CPDE4D
SCHEMBL30149847 0.82 POLB (0.46) CFTRPDE4BPDE4APDE4CPDE4D
SCHEMBL21381637 0.77 OPRD1 (0.56) PTAFRRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL30567989 0.77 OPRD1 (0.56) PTAFRRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL22773311 0.75 MEN1 (0.42) GPR119FNTAFNTBGRM5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 — — US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 — — EP disclosed
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 — — US disclosed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420961-B2 Heterocyclic compounds LPXN, MLX, CCNY PTAFR 4511/4885CFTR 2591/4885RAB9A 1129/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC PTAFR 4510/4885CFTR 4149/4885RAB9A 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback